EUCTR2017-002751-28-BE进行中（未招募）1 期
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects with Multiple Osteochondromas - MO-Ped Trial
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Written, signed, and dated informed subject/parent consent and age appropriate assent (performed according to local regulations).
- •2. A clinical diagnosis of MO with a disease-causing Ext1 or Ext2 mutations confirmed by a central laboratory.
- •3. Male and female subjects with a chronological age of 2-14 years, inclusive.
- •4. Female subjects must be premenarchal at screening.
- •5. Bone age at screening of =14 years, 0 months per the Greulich-Pyle method as assesed by a central reader.
- •6. Symptomatic MO, defined as the occurrence of any one of the following at screening:
- •Five or more clinically-evident OCs and the presence of a new or enlarging OC in the preceding 12 months.
- •Five or more clinically-evident OCs and the presence of a painful OC.
- •A skeletal deformity.
- •A joint limitation.
- •Prior surgery for a MO-related complication.
- •7. If a subject had a prior surgery for MO, the subject should not be screened until at least 8 weeks post-surgery to allow for at least 12 weeks of stabilization of symptoms prior to first dose. Surgical orthopedic implants are allowed if they were in situ for =12 weeks prior to the baseline MRI.
- •8. If a subject is currently receiving pain medications, the dose must be stable (ie, <20% variance) for 2 weeks prior to screening.
- •9. The ability to undergo whole body MRI with or without sedation/general anesthesia.
- •10. Male and female subjects of child bearing potential who are heterosexually active must agree to use two effective methods of birth control, one of which must be highly effective during treatment, and for 1 month after treatment discontinuation, unless they commit to true abstinence from heterosexual sex. Heterosexually active females of child bearing potential (FOCBP) must also agree to start effective methods of birth control at screening. An FOCBP is defined as a female who is =13 years of age or is post-menarchal, whichever is earlier.
- •11. Subjects must be accessible for treatment with study drug and follow-up.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 240
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. A weight <10 kg.
- •2. Other known syndromic conditions such as Langer-Giedion or Potocki Shaffer.
- •3. Any subject with neurologic signs suggestive of spinal cord impingement.
- •4. If subject is currently using vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment. For eligibility, no washout is required prior to the first dose of study drug.
- •5. Exposure to synthetic oral retinoids within 4 weeks prior to enrollment.
- •6. Concurrent treatment with tetracycline or any tetracycline derivatives, due to the potential increased risk of pseudotumor cerebri.
- •7. History of allergy or hypersensitivity to retinoids, gelatin or lactose (other than lactose intolerance).
- •8. Concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity.
- •9. Amylase or lipase >2 times the above the upper limit of normal (>2×ULN) or with a history of chronic pancreatitis.
- •10. Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5x ULN.
- •11. Fasting triglycerides >400 mg/dL with or without therapy.
- •12. Subjects with uncontrolled cardiovascular, renal, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease. These include subjects requiring glucocorticoid at doses >0.2mg/kg or up to 10 mg prednisone equivalent daily.
- •13. Subjects experiencing suicidal ideation (type 4 or 5) or any suicidal behavior within the past month or any suicidal behavior within the past year as defined by the Columbia-Suicide Severity Rating Scale (C SSRS).
- •14. Subjects unable or unwilling to complete the study or all study-related procedures, including imaging.
- •15. Any surgical implant that is contraindicated for MRI. Dental braces are permitted.
- •16. Participation in any clinical research study within 4 weeks prior to enrollment or simultaneous participation in any clinical research study.
- •17. Any reason that, in the opinion of the Investigator, would lead to the inability of the subject and/or family to comply with the protocol.
研究者
相似试验
进行中（未招募）
1 期
Clinical Study of Inhaled GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)Pulmonary Arterial Hypertension (PAH)MedDRA version: 20.0Level: LLTClassification code 10077739Term: Pulmonary arterial hypertension WHO functional class ISystem Organ Class: 100000004855EUCTR2019-002669-37-ATGB002, Inc.80
进行中（未招募）
1 期
A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection FractioHeart failure (HF) with reduced ejection fraction (HFrEF)MedDRA version: 26.1Level: LLTClassification code: 10078289Term: Heart failure with reduced ejection fraction Class: 10007541CTIS2023-508736-62-00Cardurion Pharmaceuticals Inc.400
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-DEAbbVie Deutschland GmbH & Co. KG160
招募中
1 期
Efficacy and Safety of Rosnilimab in Subjects with Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code: 10045365Term: Ulcerative colitis Class: 10017947CTIS2023-508679-34-00Anaptysbio Inc.147
进行中（未招募）
1 期
This is a Study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentSubjects with Polymyalgia Rheumatica (PMR) Dependent on Glucocorticoid TreatmentMedDRA version: 21.0Level: PTClassification code 10036099Term: Polymyalgia rheumaticaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2021-000648-23-ITABBVIE DEUTSCHLAND GMBH & CO. KG200